Clinical trial
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination…
NCT00094653 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00094653 |
|---|---|
| Title | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma |
| Official title | A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma, Metastases |
| Intervention type | Biological, Drug |
| Interventions | MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine |
| Enrollment | 1,783 |
| Start date | Sep 1, 2004 |
| Primary completion | Aug 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Oct 22, 2004 |
| Last update posted | Jul 11, 2011 |
| Countries | Argentina, Belgium, Brazil, Canada, Chile, France, Germany, Hungary, Netherlands, South Africa, Switzerland, United Kingdom and 1 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: